Latest News

Search News
Categories
Archives
STORMing Cancer shortlisted for Cancer Research UK’s Grand Challenge Award

8th February 2018

STORMing Cancer, a team of multi-disciplinary scientists including our own Dr Stuart McDonald, from the Centre for Tumour Biology, has been shortlisted to the final stages of Cancer Research UK (CRUK)’s Grand Challenge Award- the world’s most ambitious cancer research grant consisting of a series of £20 million awards seeking researchers to tackle cancer’s toughest challenges. In their proposed […]

Read more

World Cancer Day 2018- unite in the fight against cancer

2nd February 2018

This Sunday, 4th February, is World Cancer Day and marks a day for us all to unite against cancer in a bid to beat this disease sooner. There are over 200 types of cancer, and the money raised by fundraisers on behalf of several charities allows for researchers to identify and develop new diagnostic tools and treatments to fight cancer. Thanks to the efforts of the public and the charities, money raised for cancer research has helped double some cancer survival rates in the last 40 years.

Read more

Staying connected: New developments for tissue banking bioinformatics

1st February 2018

A team of researchers at the Barts Cancer Institute (BCI) of Queen Mary University of London have developed new analytical tools to aid in the analysis of tissue bank (TB) samples, which are an extremely valuable resource for scientists.

Read more

Researchers use flu-like virus to attack pancreatic cancer

25th January 2018

A flu-like virus has now been used in experiments to successfully inhibit the growth of pancreatic cancer, according to an early study by researchers at the Barts Cancer Institute (BCI) of Queen Mary University of London (QMUL).

Read more

Steps towards the development of a new immunotherapy for pancreatic cancer

23rd January 2018

A research team led by Professor Yaohe Wang at the Barts Cancer Institute (BCI) of Queen Mary University of London (QMUL) has created a novel oncolytic viral agent expressing interleukin-12 (IL-12) that shows promise as a potential anti-tumour immunotherapy for the treatment of pancreatic cancer.

Read more

Cost-effective testing for breast and ovarian cancer gene mutations

18th January 2018

Screening the entire population for breast and ovarian cancer gene mutations, as opposed to just those at high-risk of carrying this mutation, is cost effective and could prevent more ovarian and breast cancers than the current approach, according to research led by Barts Cancer Institute of Queen Mary University of London. The researchers believe that implementing a programme to test all British women over 30 years of age could result in thousands of fewer cases of ovarian and breast cancer; up to 17,000 fewer ovarian cancers and 64,000 fewer breast cancers over a lifetime.

Read more

Search News
Categories
Archives